These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

More than 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

LAS VEGAS, NV / / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ('Avant' or the 'Company'), and its partner, Ainnova Tech, Inc., (Ai ...

USA News Group News Commentary ? Weeks after the monumental $500-billion announcement of Project Stargate, which includes aims to transform healthcare, a growing number of health executives are seeing ...

USA News Group News Commentary – Just weeks after the groundbreaking $500-billion announcement of Project Stargate, which aims to redefine the future of healthcare, industry ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

If all this sounds familiar, you’re probably thinking of Theranos, but SiPhox says their product really works and could be in ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has completed its acquisition of Ambry Genetics, a ...

LAS VEGAS, NV / ACCESS Newswire / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology ...